Acute Ischemic Stroke Management in Patients with Atrial Fibrillation

Acute Stroke Management

The American Heart Association/American Stroke Association guidelines recommend administering IV tissue plasminogen activator (tPA) if the patient presents within 3 hours of clearly defined symptom onset, provided there are no other contraindications 1
The 2012 AHA/ASA guidelines noted uncertainty about whether patients on novel oral anticoagulants like apixaban can be safely treated with thrombolysis, as this was an unresolved issue at the time of guideline publication 2

For patients with atrial fibrillation who suffer an ischemic stroke while on therapeutic anticoagulation, the American Heart Association recommends continuing the same anticoagulant regimen 3
The American College of Cardiology recommends against increasing anticoagulation intensity or adding antiplatelet agents, as both strategies increase bleeding risk without reducing ischemic events 3
Apixaban demonstrated superiority over warfarin in the ARISTOTLE trial for stroke prevention in atrial fibrillation patients, with lower rates of stroke, systemic embolism, major bleeding, and mortality 4

For large strokes with extensive infarct burden or hemorrhagic transformation, the American College of Chest Physicians recommends delaying anticoagulation beyond 2 weeks 1

The American College of Chest Physicians recommends administering prophylactic-dose subcutaneous low-molecular-weight heparin (LMWH) or intermittent pneumatic compression devices for patients with restricted mobility 1
Prophylactic-dose LMWH is preferred over unfractionated heparin for venous thromboembolism prophylaxis 1
The American College of Cardiology states that the presence of hypertrophic obstructive cardiomyopathy (HOCM) does not alter anticoagulation management for atrial fibrillation-related stroke 4

The American Heart Association recommends monitoring renal function regularly, as apixaban is partially renally excreted and dose adjustment is required for severe renal impairment 5
Patients should be assessed for bleeding complications, particularly gastrointestinal bleeding, which is the most common site of major bleeding with anticoagulants 5
The American Stroke Association emphasizes the importance of counseling the patient on medication adherence, as apixaban's short half-life means that missed doses rapidly lose anticoagulant effect and increase thrombotic risk 2